Real-World Effectiveness of Seasonal Influenza Vaccines During the 2024–2025 Season: Subgroup Analyses by Virus Subtype, Time Since Vaccination, and Diagnostic Method
Authors:
- Yu Jung ChoiYCYu Jung Choi
- Jungmin LeeJLJungmin Lee
- Joon Young SongJSJoon Young Song
- Seong-Heon WieSWSeong-Heon Wie
- Jacob LeeJLJacob Lee
- Jin-Soo LeeJLJin-Soo Lee
- Hye Won JeongHJHye Won Jeong
- Joong Sik EomJEJoong Sik Eom
- Jang Wook SohnJSJang Wook Sohn
- Young Kyung YoonYYYoung Kyung Yoon
- Won Suk ChoiWCWon Suk Choi
- Eliel NhamENEliel Nham
Open Access
Abstract
Background/Objectives: Despite high vaccination coverage, influenza remains a public health concern in South Korea, particularly in older adults. Continuous evaluation of vaccine effectiveness (VE) is essential to optimize immunization strategies. Methods: This study evaluated seasonal influenza VE for preventing laboratory-confirmed influenza using a test-negative design through a hospital-based influenza surveillance system in South Korea from 1 November 2024, to 30 April 2025. Demographic and clinical information was collected through questionnaire surveys and electronic medical records. Influenza was diagnosed using rapid antigen tests (RATs) and reverse transcription polymerase chain reaction (RT-qPCR), and vaccine effectiveness was analyzed using multivariable logistic regression. Results: In total, 3954 participants were included, with 1977 influenza-positive cases and 1977 test-negative controls. Influenza A and B accounted for 93.1% and 7.0% of cases, respectively. The adjusted overall VE was 20.4% (95% confidence interval [CI], 8.2–30.9; p = 0.002). VE was higher in adults aged 50–64 years (46.8%) than in those aged ≥65 years (18.8%). VE was 19.9% against influenza A and 45.7% against A/H3N2. VE was higher among individuals tested using RT-qPCR than among those tested using RATs (21.5% vs. 15.7%), and was also greater during the early period than during the late period (20.5% vs. 11.4%). Vaccination did not reduce influenza-associated hospitalization risk (VE, 17.3%; 95% CI, −9.3 to 37.4). A significant reduction in hospitalization risk was observed in adults aged 50–64 years (VE, 46.8%), with no significant benefit in those aged ≥65 years. Conclusions: The 2024–2025 seasonal influenza vaccine provided moderate protection against laboratory-confirmed influenza in adults, with higher effectiveness in those aged 50–64 years.Keywords
Funding Information
- Korea University College of Medicine (Q2204881)
This publication has 18 references indexed in Scilit:
- Real-world effectiveness of influenza vaccine over a decade during the 2011–2021 seasons—Implications of vaccine mismatchVaccine, 2024
- Diagnostic accuracy of point-of-care tests in acute community-acquired lower respiratory tract infections. A systematic review and meta-analysisClinical Microbiology and Infection, 2022
- Factors That Influence the Immune Response to VaccinationClinical Microbiology Reviews, 2019
- Cell culture-derived influenza vaccines in the severe 2017–2018 epidemic season: a step towards improved influenza vaccine effectivenessnpj Vaccines, 2018
- Effectiveness of influenza vaccines in preventing severe influenza illness among adults: A systematic review and meta-analysis of test-negative design case-control studiesJournal of Infection, 2017
- Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectivenessVaccine, 2015
- Understanding immunosenescence to improve responses to vaccinesNature Immunology, 2013
- Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed InfluenzaClinical Infectious Diseases, 2013
- Vaccines for the elderlyClinical Microbiology and Infection, 2012
- Comparison of influenza vaccine effectiveness using different methods of case detection: Clinician-ordered rapid antigen tests vs. active surveillance and testing with real-time reverse-transcriptase polymerase chain reaction (rRT-PCR)Vaccine, 2011